Longifene Tablet contains Buclizine 25mg, an antihistaminic agent primarily used for the prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness and vertigo. Buclizine acts by antagonizing central and peripheral histamine H1 receptors, thereby reducing the excitability of the vestibular apparatus and suppressing the vomiting center in the brain. This medication is indicated for patients experiencing symptoms related to vestibular disturbances, including motion sickness and Ménière’s disease. Longifene Tablet is typically administered orally, with dosage tailored according to the severity of symptoms and patient response. It is generally well tolerated; however, common adverse effects may include drowsiness, dry mouth, and occasional gastrointestinal discomfort. Caution is advised when used in patients with a history of glaucoma, prostatic hypertrophy, or urinary retention due to its anticholinergic properties. Concomitant use with alcohol or other central nervous system depressants may potentiate sedative effects. Longifene should be used under medical supervision, especially in pregnant or lactating women and individuals with hepatic or renal impairment. Proper adherence to prescribed dosage and duration of therapy is essential to ensure optimal therapeutic outcomes and minimize potential side effects.